# Age-targeted vaccination for reducing Clostridioides difficile infection in England: a coupled mathematical-economic modelling analysis.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12261565</article-id><article-id pub-id-type="pmid">40660272</article-id>
<article-id pub-id-type="publisher-id">4265</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04265-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Age-targeted vaccination for reducing <italic>Clostridioides difficile</italic> infection in England: a coupled mathematical-economic modelling analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Yakob</surname><given-names>Laith</given-names></name><address><email>Laith.Yakob@AdelphiValues.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Allel</surname><given-names>Kasim</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Elragig</surname><given-names>Aiman</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Planche</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Mugwagwa</surname><given-names>Tendai</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mo&#x000ef;si</surname><given-names>Jennifer C.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Holly</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00a0jsq62</institution-id><institution-id institution-id-type="GRID">grid.8991.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0425 469X</institution-id><institution>Antimicrobial Resistance Centre, London School of Hygiene &#x00026; Tropical Medicine, </institution></institution-wrap>London, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00a0jsq62</institution-id><institution-id institution-id-type="GRID">grid.8991.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0425 469X</institution-id><institution>Department of Disease Control, Faculty of Infectious &#x00026; Tropical Diseases, London School of Hygiene &#x00026; Tropical Medicine, </institution></institution-wrap>London, UK </aff><aff id="Aff3"><label>3</label>Current Address: Adelphi Values, Bankside 3, 90-100 Southwark St, London, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052gg0110</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Present address: Nuffield Department of Primary Care Health Sciences, </institution><institution>University of Oxford, </institution></institution-wrap>Oxfordshire, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0312pnr83</institution-id><institution-id institution-id-type="GRID">grid.48815.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 2153 2936</institution-id><institution>Present address: De Montford University, </institution></institution-wrap>Leicester, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040f08y74</institution-id><institution-id institution-id-type="GRID">grid.264200.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 8546 682X</institution-id><institution>Institute of Infection and Immunity, St George&#x02019;s University of London, </institution></institution-wrap>London, UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04x4v8p40</institution-id><institution-id institution-id-type="GRID">grid.418566.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9348 0090</institution-id><institution>Pfizer, Inc, </institution></institution-wrap>Walton Oaks, UK </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02c9yny10</institution-id><institution-id institution-id-type="GRID">grid.476471.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0593 9797</institution-id><institution>Pfizer, Inc, </institution></institution-wrap>Paris, France </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xdqrp08</institution-id><institution-id institution-id-type="GRID">grid.410513.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 8800 7493</institution-id><institution>Pfizer, Inc, </institution></institution-wrap>Collegeville, PA USA </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>426</elocation-id><history><date date-type="received"><day>9</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>7</day><month>7</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025, corrected publication 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1"><italic>Clostridioides difficile</italic> infection (CDI) is associated with high morbidity and mortality, emphasising the need for prophylaxis. The lead vaccine candidate recently demonstrated promising reductions in medically attended cases.</p></sec><sec><title>Methods</title><p id="Par2">Key risk factors for CDI were incorporated into a hospital-level mathematical model used to simulate the impact of the vaccine on reducing disease burden in England. Model outputs of interest included medically attended cases, intensive care admissions and deaths associated with CDI, as well as costs and quality-adjusted life years (QALYs). Hospital costs and costs of years of life lost due to premature mortality averted per vaccine course were computed for a 10-year time horizon.</p></sec><sec><title>Results</title><p id="Par3">The epidemiological model demonstrated considerable benefits to targeting older age groups whereby vaccinating only those over the age of 74 years old (i.e. 9% of England&#x02019;s population) more than halved CDI cases and intensive care unit (ICU) admissions. Simulations also showed that this could be expected to reduce deaths by almost two-thirds and that around 20% of lives saved would be achieved through indirect benefits, i.e. due to reduced transmission to unvaccinated as well as vaccinated individuals. Issuing around 5 million vaccine courses in both the first and second year to protect the eldest, and 0.4 million annual courses thereafter to maintain effective coverage of all those over 64 years old, can be expected to avert &#x000a3;378 in costs (2023&#x000a3;) and gain 0.046 QALYs per vaccine course by the fourth year of rollout.</p></sec><sec><title>Conclusions</title><p id="Par4">Should a safe and efficacious <italic>C. difficile</italic> vaccine be licensed, it could be positioned very well for providing considerable economical and health benefits. This work guides how these gains could be maximised for England&#x02019;s population.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04265-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Transmission dynamics</kwd><kwd><italic>C. difficile</italic></kwd><kwd>Vaccine</kwd><kwd>QALY</kwd><kwd>Disease control</kwd><kwd>Health economics</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par13"><italic>Clostridioides difficile</italic>, a gram-positive obligate anaerobe, remains the leading cause of healthcare-associated infectious diarrhoea and is also increasingly associated with community-associated disease [<xref ref-type="bibr" rid="CR1">1</xref>]. There are 120,000 reported infections in Europe each year, with England alone accounting for around 10% of these cases, though these are likely underestimates due to lack of clinical awareness and inappropriate diagnostic testing [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Symptomatic <italic>C. difficile </italic>infection (CDI) ranges from mild diarrhoea to severe illness which may lead to complications such as pseudomembranous colitis, toxic megacolon, sepsis and death [<xref ref-type="bibr" rid="CR4">4</xref>]. Treatment failure is common, leading to the reemergence of symptoms, necessitating complex treatment plans and worsened prognosis [<xref ref-type="bibr" rid="CR5">5</xref>]. Recurrent infections impose considerably higher costs to manage, mostly driven through prolonged patient length of stay in hospitals [<xref ref-type="bibr" rid="CR6">6</xref>]. The high morbidity and mortality associated with <italic>C. difficile</italic> infection, along with the difficulties associated with its effective treatment, has led to it being declared an urgent public health threat by the US Centers for Disease Control and Prevention [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par14">Age is a major risk factor for CDI and associated deaths, with&#x02009;&#x0003e;&#x02009;80% of deaths due to CDI occurring in those over 65 years old [<xref ref-type="bibr" rid="CR8">8</xref>]. In addition to age, a recent multi-centred European multivariate analysis identified prior hospital admission (odds ratio, &#x02018;OR&#x02019;: 1.7) and number of antibiotics taken (OR:1.2) retained significance as risk factors for primary (first episode) CDI across multiple populations [<xref ref-type="bibr" rid="CR9">9</xref>]. While over a dozen risk factors have been implicated in the clinical literature (including underlying conditions such as inflammatory bowel disease and cancer; weakened immunity due to diabetes or chemotherapy treatment; exposure to PPIs), age, previous CDI, antibiotic exposure and prior hospital admission are ubiquitously associated not only with primary CDI but also with recurrent (i.e. return of CDI symptoms after the treatment of a primary episode) CDI and CDI-associated mortality [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par15">Current methods for reducing <italic>C. difficile</italic> transmission and CDI risk in the healthcare setting include patient isolation, antimicrobial stewardship, improved hand hygiene, environmental cleaning and reduced hospital length of stay. Fidaxomicin is currently the preferred treatment option by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America (IDSA/SHEA) [<xref ref-type="bibr" rid="CR11">11</xref>]. More recently there has been increasing consensus among health authorities recommending faecal microbiota transfer (FMT) for use in second (ESCMID) or third recurrences (IDSA/SHEA) [<xref ref-type="bibr" rid="CR12">12</xref>]. FMT can be delivered through either the upper or lower gastrointestinal (GI) tract, both risking rare complications (aspiration and colonic perforation, respectively) [<xref ref-type="bibr" rid="CR13">13</xref>]. There is no consensus in the superiority of either route, but results from a meta-analysis indicated a threefold increased hazard of treatment failure after 30 days following upper GI delivery (hazard ratio 3.43, 1.32&#x02013;8.92) [<xref ref-type="bibr" rid="CR14">14</xref>]. In 2023, the US Food and Drug Administration approved the first faecal microbiota product to be taken orally to prevent CDI recurrence [<xref ref-type="bibr" rid="CR15">15</xref>], so this method can be expected to feature in more CDI control programmes.</p><p id="Par16">Typically, an assortment of control methods is used to varying degrees and it is not possible to disentangle the relative contributions of individual control methods used in a &#x02018;bundled&#x02019; approach. However, their differential, concerted contribution has been reported to reduce CDI by 33&#x02013;61% [<xref ref-type="bibr" rid="CR16">16</xref>]. An economic evaluation conducted by Brain et al. explored FMT, antimicrobial stewardship, improved hand hygiene and environmental cleaning demonstrated that a bundled approach of improved hand hygiene and environmental cleaning produced superior health benefits and cost-savings, along with the highest mean net monetary benefit [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par17">In 2022, results were released from the CLOVER trial (<underline>CLO</underline>stridium difficile <underline>V</underline>accine <underline>E</underline>fficacy T<underline>R</underline>ial)&#x02014;an international, phase 3, placebo-controlled and randomised study to evaluate the efficacy, safety and tolerability of the leading <italic>C. difficile</italic> vaccine candidate, PF-06425090 [<xref ref-type="bibr" rid="CR18">18</xref>]. Though the trial did not meet its primary endpoint of prevention of primary CDI, it demonstrated 100% vaccine efficacy in reducing medically attended CDI, and safety reviews indicated that the investigational vaccine was safe and well tolerated. Here, a novel mathematical model of <italic>C. difficile</italic> transmission is presented and linked with the costs and utilities associated with morbidity and mortality, in order to evaluate the projected benefit of deploying a safe and efficacious <italic>C. difficile</italic> vaccine in England.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Epidemiological compartment model framework</title><p id="Par18">A deterministic compartment model was developed to simulate the transition between epidemiological states of a population of hospital inpatients (see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>The epidemiological states of the <italic>C. difficile</italic> model. Susceptible individuals (S) become colonised (C) and then diseased (D), with the sum total of patients denoted by &#x02018;<italic>N</italic>&#x02019;. &#x02018;Diseased&#x02019; inpatients pertain to those who are medically attended cases of CDI. Superscripts II and III depict those who have recently recovered from primary and recurrent CDI, respectively. Patients who have recovered from CDI and who subsequently remain uncolonised for 8 weeks return to starting epidemiological categories. &#x02018;ICU&#x02019; superscripts are used for those who are receiving intensive care. Patients among half-shaded compartments are not discharged and the shaded compartment denotes patients not discharged from ICU. Subscripts are described in the main text</p></caption><graphic xlink:href="12916_2025_4265_Fig1_HTML" id="MO1"/></fig></p><p id="Par19">Subscripts denote those who are taking, or have taken within the past 3 months, antibiotics (A); those who were discharged from hospital less than 1 month prior (H); and those who have both recently taken antibiotics and been recently discharged (H,A). Individuals who have neither received antibiotics nor been discharged recently make up the remainder (0). It was assumed that the heightened vulnerability of patients who were previously admitted to hospital in the month preceding current admission would not be expected to wane following their current admission. Similarly, patients are more likely to be exposed to antibiotics following admission (e.g. likelihood of being on antibiotics is substantially higher for inpatients [<xref ref-type="bibr" rid="CR19">19</xref>]. In this way, the model does not account for the small number of patients who are admitted to hospital having received antibiotics recently but who, following admission to hospital, no longer are taking antibiotics&#x02014;and who remain in hospital for long enough for their gut flora to fully recover (in our model, we assumed this takes 3 months [<xref ref-type="bibr" rid="CR20">20</xref>]. For simplicity, beyond primary CDI, recent antibiotic exposure and recent hospital stay are superseded by recent recovery from medically attended CDI. This means for recurrent cases, prior CDI and age inform risk. This is in agreement with the ESCMID 2021 update on the treatment guidance document for Clostridioides difficile infection in adults [<xref ref-type="bibr" rid="CR21">21</xref>]</p><p id="Par20">Of note for this pathogen&#x02019;s life history, there is an important distinction between those who are asymptomatically colonised (&#x02018;C&#x02019; in the model&#x02019;s variables) and those who are symptomatically diseased (&#x02018;D&#x02019; in the model&#x02019;s variables). Both epidemiological categories are known to transmit infection but there are limited data available to inform their relative contributions. Direct measurement of disease transmission in a population setting is not trivial and models typically infer transmission rates from infection levels. Here, there was not only interest in ascertaining the overall transmission rate but also how transmission was distributed from asymptomatically colonised compared with diseased individuals, to determine the value of &#x003bd; (the relative transmissibility from diseased individuals). To achieve this, estimates of their respective proportional contributions generated by Eyre et al. were used [<xref ref-type="bibr" rid="CR22">22</xref>]. In their study, plausible epidemiologic links among genetically related cases were sought and the authors identified that 45% of cases appeared to have been transmitted from sources other than symptomatic patients [<xref ref-type="bibr" rid="CR22">22</xref>]. Thus, &#x003bd; was calibrated to simulate the result from Eyre et al. whereby 55% of the force of infection originated from symptomatic patients while the remaining 45% originated from asymptomatic (colonised) patients.</p><p id="Par21">Although not included in the figure, each epidemiological state is duplicated according to four age strata: under 65 year olds, 65&#x02013;74 year olds, 75&#x02013;84 year olds and over 84 year olds. These different risk strata (recent hospitalisation, recent antibiotic exposure and age) inform the rates of colonisation and rates of CDI development (see &#x02018;<xref rid="Sec6" ref-type="sec">Risk stratification</xref>&#x02019;). Patients of all epidemiological states may be admitted (see &#x02018;Admission Calculations&#x02019; in supplementary materials) but only those who are not diseased and not in the ICU can be discharged. It is assumed that those with CDI in the ICU remain within the ICU until the infection is cleared. CDI-related deaths are tracked. Equations describing the model dynamics are shown below, with parameter definitions and values described in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Parameter definitions and baseline values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Definition (units)</th><th align="left">Stratified by risk</th><th align="left">Baseline value</th><th align="left">Source</th></tr></thead><tbody><tr><td align="left"><italic>&#x003b1;</italic></td><td align="left">Rate of admissions (per day)</td><td align="left">Yes</td><td align="left" colspan="2">See Additional file 1</td></tr><tr><td align="left"><italic>&#x003b2;</italic></td><td align="left">Rate of acquisition of colonisation (per day)&#x02020;</td><td align="left">Yes</td><td align="left">0.021<sup>a</sup></td><td align="left">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left"><italic>&#x003bd;</italic></td><td align="left">Fold increase in transmission from diseased versus colonised individual&#x02020;</td><td align="left">No</td><td align="left">36<sup>b</sup></td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left"><italic>&#x003b3;</italic></td><td align="left">Loss of colonisation (per day)&#x02020;</td><td align="left">No</td><td align="left">0.03</td><td align="left">[<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr><td align="left"><italic>&#x003b4;</italic></td><td align="left">Rate of discharge (per day)</td><td align="left">Yes</td><td align="left">0.16</td><td align="left">[<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td align="left"><italic>&#x003b5;</italic></td><td align="left">Recovery from CDI (per day)&#x02020;</td><td align="left">No</td><td align="left">0.07</td><td align="left">[<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left"><italic>&#x003ba;</italic></td><td align="left">Rate of ICU admission of CDI patients (per day)</td><td align="left">No</td><td align="left">0.0147<sup>c</sup></td><td align="left">[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left"><italic>&#x003bb;</italic></td><td align="left">Rate of ICU discharge (per day)</td><td align="left">No</td><td align="left">0.25</td><td align="left">[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left"><italic>&#x003bc;</italic></td><td align="left">CDI-related mortality rate (per day)&#x02020;</td><td align="left">Yes</td><td align="left">0.0036<sup>d</sup></td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left"><italic>&#x003bc;</italic><sup><italic>II</italic></sup></td><td align="left">Primary recurrent CDI mortality rate (per day)</td><td align="left">No</td><td align="left">1.88&#x02009;&#x000d7;&#x02009;<italic>&#x003bc;</italic></td><td align="left">[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left"><italic>&#x003bc;</italic><sup><italic>III</italic></sup></td><td align="left">Second recurrent CDI mortality rate (per day)</td><td align="left">No</td><td align="left">2.38&#x02009;&#x000d7;&#x02009;<italic>&#x003bc;</italic></td><td align="left">[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left"><italic>&#x003bc;</italic><sup><italic>ICU</italic></sup></td><td align="left">Background ICU mortality rate (per day)</td><td align="left">No</td><td align="left">0.0424<sup>e</sup></td><td align="left">[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td align="left"><italic>&#x003c1;</italic></td><td align="left">Cleared colonisation post treatment (proportion)&#x02020;</td><td align="left">No</td><td align="left">0.5</td><td align="left">[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td align="left"><italic>&#x003c3;</italic></td><td align="left">Rate of developing CDI (per day)&#x02020;</td><td align="left">Yes</td><td align="left">4.45&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;4</sup></td><td align="left">[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left"><italic>&#x003c4;</italic></td><td align="left">Rate of starting antibiotic treatment (per day)</td><td align="left">No</td><td align="left">0.044<sup>f</sup></td><td align="left">[<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td align="left"><italic>&#x003c6;</italic></td><td align="left">Rate of transition from &#x02018;recurrence&#x02019; (per day)&#x02020;</td><td align="left">No</td><td align="left">0.018<sup>g</sup></td><td align="left">[<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td align="left"><italic>&#x003c9;</italic></td><td align="left">Rate of ICU admission of non-CDI patients (per day)</td><td align="left">No</td><td align="left" colspan="2">See Additional file 1</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>This is the daily rate required to ensure 5.8% of inpatients were colonised, following a recent, comprehensive study conducted in France [<xref ref-type="bibr" rid="CR23">23</xref>]</p><p><sup>b</sup>A detailed description of how this was estimated is in the Methods main text</p><p><sup>c</sup>18.6% of in-hospital CDI is categorised as &#x02018;severe&#x02019;, and assuming CDI requires, on average, 2 weeks for recovery [<xref ref-type="bibr" rid="CR26">26</xref>], means the daily rate of developing disease severe enough for ICU admission is calculated as&#x02009;&#x02212;&#x02009;ln(1&#x02009;&#x02212;&#x02009;0.186)/14&#x02009;=&#x02009;0.0147</p><p><sup>d</sup>Calculated by 30-day all-cause mortality data from 2019/20 indicating that 14.9% die within 30 days and subtracting the crude 30-day mortality rate of 4.6% found by Ruiz et al. [<xref ref-type="bibr" rid="CR35">35</xref>] (i.e.&#x02009;&#x02212;&#x02009;ln(1&#x02009;&#x02212;&#x02009;(0.149&#x02009;&#x02212;&#x02009;0.046))/30&#x02009;=&#x02009;0.0036)</p><p><sup>e</sup>Calculated by averaged total mortality from pan-European study yielding 15.6% [<xref ref-type="bibr" rid="CR32">32</xref>] and allowing for 4-day average length of stay [<xref ref-type="bibr" rid="CR29">29</xref>], i.e.&#x02009;&#x02212;&#x02009;ln(1&#x02009;&#x02212;&#x02009;0.156)/4&#x02009;=&#x02009;0.0424</p><p><sup>f</sup>23.4% of inpatients in western Europe were recently shown to be taking antibiotics, necessitating a daily rate of starting a course of antibiotics to be&#x02009;&#x02212;&#x02009;ln(1&#x02009;&#x02212;&#x02009;0.234)/<italic>&#x003b4;</italic><sup>&#x02212;1</sup>&#x02009;=&#x02009;0.044, i.e. this is an all-cause antibiotic treatment rate</p><p><sup>g</sup>Reciprocal of the duration after which a CDI case would no longer be considered recurrent. &#x02020;<italic>C</italic>. <italic>difficile</italic> life history traits were included in a global (Sobol) sensitivity analysis (see Additional file 2) [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]</p></table-wrap-foot></table-wrap><disp-formula id="Equa"><alternatives><tex-math id="d33e893">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{S}_{O,i}}{dt}={\alpha }_{{S}_{O},i}+\gamma {C}_{O,i}-\left(\tau +\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}+{\delta }_{i}\right){S}_{O,i}$$\end{document}</tex-math><mml:math id="d33e898" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>O</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003c4;</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equa.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equb"><alternatives><tex-math id="d33e959">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{S}_{A,i}}{dt}={\alpha }_{{S}_{A},i}+\gamma {C}_{A,i}+\tau {S}_{O,i}-\left(\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}+{\delta }_{i}\right){S}_{A,i}$$\end{document}</tex-math><mml:math id="d33e964" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003c4;</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equb.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equc"><alternatives><tex-math id="d33e1032">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{S}_{H,i}}{dt}={\alpha }_{{S}_{H},i}+\gamma {C}_{H,i}-\left(\tau +\frac{{\beta }_{H}\left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}+{\delta }_{i}\right){S}_{H,i}$$\end{document}</tex-math><mml:math id="d33e1037" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003c4;</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equc.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equd"><alternatives><tex-math id="d33e1100">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{S}_{H,A,i}}{dt}={\alpha }_{{S}_{H,A},i}+\gamma {C}_{H,A,i}+\tau {S}_{H,i}+\varphi \left({S}_{i}^{II}+{S}_{i}^{III}\right)-\left(\frac{{\beta }_{H}\left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}+{\delta }_{i}\right){S}_{H,A,i}$$\end{document}</tex-math><mml:math id="d33e1105" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003c4;</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003c6;</mml:mi><mml:mfenced close=")" open="("><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mfenced><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equd.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Eque"><alternatives><tex-math id="d33e1202">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{C}_{O,i}}{dt}={\alpha }_{{C}_{O},i}+\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}{S}_{O,i}-\left(\tau +\gamma +{\sigma }_{O,i}+{\delta }_{i}\right){C}_{O,i}$$\end{document}</tex-math><mml:math id="d33e1207" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>O</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003c4;</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Eque.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equf"><alternatives><tex-math id="d33e1276">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{C}_{A,i}}{dt}={\alpha }_{{C}_{A},i}+\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}{S}_{A,i}+\tau {C}_{O,i}-\left(\gamma +{\sigma }_{A,i}+{\delta }_{i}\right){C}_{A,i}$$\end{document}</tex-math><mml:math id="d33e1281" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003c4;</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003b3;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equf.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equg"><alternatives><tex-math id="d33e1356">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{C}_{H,i}}{dt}={\alpha }_{{C}_{H},i}+\frac{{\beta }_{H}\left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}-\left(\tau +\gamma +{\sigma }_{H,i}+{\delta }_{i}\right){C}_{H,i}$$\end{document}</tex-math><mml:math id="d33e1361" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003c4;</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equg.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equh"><alternatives><tex-math id="d33e1425">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{C}_{H,A,i}}{dt}={\alpha }_{{C}_{H,A},i}+\frac{{\beta }_{H}\left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}+\tau {C}_{H,i}-\left(\gamma +{\sigma }_{H,A,i}+{\delta }_{i}\right){C}_{H,A,i}$$\end{document}</tex-math><mml:math id="d33e1430" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mi>&#x003c4;</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003b3;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equh.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equi"><alternatives><tex-math id="d33e1509">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{D}_{i}}{dt}={\alpha }_{D,i}+{\sigma }_{O,i}{C}_{O,i}+{\sigma }_{A,i}{C}_{A,i}+{\sigma }_{H,i}{C}_{H,i}+{\sigma }_{H,A,i}{C}_{H,A,i}-\left(\varepsilon +\kappa +{\mu }_{i}\right){D}_{i}$$\end{document}</tex-math><mml:math id="d33e1514" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003b5;</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003ba;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equi.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equj"><alternatives><tex-math id="d33e1602">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{S}_{i}^{II}}{dt}={\alpha }_{{S}^{II},i}+\varepsilon \rho {D}_{i}+\gamma {C}_{i}^{II}-\left(\varphi +\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}+{\delta }_{i}\right){S}_{i}^{II}$$\end{document}</tex-math><mml:math id="d33e1607" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b5;</mml:mi><mml:mi>&#x003c1;</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003c6;</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equj.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equk"><alternatives><tex-math id="d33e1681">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{C}_{i}^{II}}{dt}={\alpha }_{{C}^{II},i}+\varepsilon (1-\rho {)D}_{i}+\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}{S}_{i}^{II}-\left(\gamma +{\sigma }_{{C}^{II},i}+{\delta }_{i}\right){C}_{i}^{II}$$\end{document}</tex-math><mml:math id="d33e1686" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>+</mml:mo><mml:mi>&#x003b5;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>&#x003c1;</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mi>D</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003b3;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equk.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equl"><alternatives><tex-math id="d33e1777">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{D}_{i}^{II}}{dt}={\alpha }_{{D}^{II},i}+{\sigma }_{{C}^{II},i}{C}_{i}^{II}-\left(\varepsilon +\kappa +{\mu }_{i}^{II}\right){D}_{i}^{II}$$\end{document}</tex-math><mml:math id="d33e1782" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003b5;</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003ba;</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup></mml:mfenced><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equl.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equm"><alternatives><tex-math id="d33e1849">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{S}_{i}^{III}}{dt}={\alpha }_{{S}^{III},i}+\varepsilon \rho \left({D}_{i}^{II}+{D}_{i}^{III}\right)+\gamma {C}_{i}^{III}+\lambda {S}_{i}^{ICU}-\left(\varphi +\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}+{\delta }_{i}\right){S}_{i}^{III}$$\end{document}</tex-math><mml:math id="d33e1854" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b5;</mml:mi><mml:mi>&#x003c1;</mml:mi><mml:mfenced close=")" open="("><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mfenced><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003c6;</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equm.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equn"><alternatives><tex-math id="d33e1950">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{C}_{i}^{III}}{dt}={\alpha }_{{C}^{III},i}+\varepsilon (1-\rho )\left({D}_{i}^{II}+{D}_{i}^{III}\right)+\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}{S}_{i}^{III}+\lambda {C}_{i}^{ICU}-\left(\gamma +{\sigma }_{{C}^{III},i}+{\delta }_{i}\right){C}_{i}^{III}$$\end{document}</tex-math><mml:math id="d33e1955" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>&#x003c1;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfenced close=")" open="("><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">II</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mfenced><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003b3;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equn.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equo"><alternatives><tex-math id="d33e2068">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{D}_{i}^{III}}{dt}={\alpha }_{{D}^{III},i}+{\sigma }_{{C}^{III},i}{C}_{i}^{III}-\left(\varepsilon +\kappa +{\mu }_{i}^{III}\right){D}_{i}^{III}$$\end{document}</tex-math><mml:math id="d33e2073" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003b5;</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003ba;</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mfenced><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">III</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equo.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equp"><alternatives><tex-math id="d33e2140">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{S}_{i}^{ICU}}{dt}={\alpha }_{{S}^{ICU},i}+\varepsilon \rho {D}_{i}^{ICU}+\sum {S}_{i}{\delta }_{i}\omega -\left(\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}+\lambda +{\mu }^{ICU}\right){S}_{i}^{ICU}$$\end{document}</tex-math><mml:math id="d33e2145" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b5;</mml:mi><mml:mi>&#x003c1;</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mi>&#x003c9;</mml:mi><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>&#x003bc;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msup></mml:mfenced><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equp.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equq"><alternatives><tex-math id="d33e2227">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{C}_{i}^{ICU}}{dt}={\alpha }_{{C}^{ICU},i}+\varepsilon \left(1-\rho \right){D}_{i}^{ICU}+\sum {C}_{i}{\delta }_{i}\omega +\frac{\beta \left(\sum {C}_{i}+\nu \sum {D}_{i}\right)}{N}{S}_{i}^{ICU}-\left({\sigma }_{{C}^{ICU},i}+\lambda +{\mu }^{ICU}\right){C}_{i}^{ICU}$$\end{document}</tex-math><mml:math id="d33e2232" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b5;</mml:mi><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>&#x003c1;</mml:mi></mml:mfenced><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mi>&#x003c9;</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mfenced close=")" open="("><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bd;</mml:mi><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>&#x003bc;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msup></mml:mfenced><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equq.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equr"><alternatives><tex-math id="d33e2335">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{D}_{i}^{ICU}}{dt}={\alpha }_{{D}^{ICU},i}+\sum {D}_{i}\kappa +{\sigma }_{{C}^{ICU},i}{C}_{i}^{ICU}-\left(\varepsilon +{\mu }_{i}+{\mu }^{ICU}\right){D}_{i}^{ICU}$$\end{document}</tex-math><mml:math id="d33e2340" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>&#x02211;</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mi>&#x003ba;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>&#x003b5;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>&#x003bc;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msup></mml:mfenced><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ICU</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="12916_2025_4265_Article_Equr.gif" position="anchor"/></alternatives></disp-formula></p></sec></sec><sec id="Sec4"><title>Risk stratification</title><p id="Par22">Parameters with values stratified by age, recent healthcare/antibiotic exposure include:<list list-type="bullet"><list-item><p id="Par23">All-cause admissions are determined by age category:&#x02009;&#x0003c;&#x02009;65 years&#x02009;=&#x02009;63%, 65&#x02013;74 years&#x02009;=&#x02009;16%, 75&#x02013;84 years&#x02009;=&#x02009;14% and&#x02009;&#x0003e;&#x02009;84 years&#x02009;=&#x02009;7% [<xref ref-type="bibr" rid="CR47">47</xref>], but also by epidemiological category (see supplementary materials).</p></list-item><list-item><p id="Par24">Rate of colonisation is known to be 2.18-fold higher among those with recent healthcare facility exposure [<xref ref-type="bibr" rid="CR48">48</xref>].</p></list-item><list-item><p id="Par25">Rate of developing disease is 6.67-fold higher among those with recent antibiotic exposure [<xref ref-type="bibr" rid="CR48">48</xref>].</p></list-item><list-item><p id="Par26">Sixty-three percent of admissions are under 65 years old but 62% of inpatients are over 65 [<xref ref-type="bibr" rid="CR49">49</xref>] means that over 65 year age categories have a longer length of stay (8.3 days) versus under 65 year olds (3 days).</p></list-item><list-item><p id="Par27">Thirty-day mortality rate is 3.3-fold higher for over 65 year olds [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR50">50</xref>].</p></list-item><list-item><p id="Par28">For over 65&#x02009;s, following colonisation, risk of developing disease increases by 4% per year of age, so, 75&#x02013;84 increases 1.4-fold, and&#x02009;&#x0003e;&#x02009;85 increases 1.8-fold [<xref ref-type="bibr" rid="CR48">48</xref>].</p></list-item></list></p><sec id="Sec5"><title>Endemic equilibria</title><p id="Par29">CDI data were open access and obtained from the UK government statistics by NHS organisation and prior trust exposure [<xref ref-type="bibr" rid="CR34">34</xref>] and from the 30-day all-cause mortality statistics in the UK Health Security Agency&#x02019;s database [<xref ref-type="bibr" rid="CR30">30</xref>]. Instead of modelling a specific trust, a 1000-bed hospital (960 general ward and 40 ICU) was simulated and CDI rates were fitted to average national incidence rates of 16.5 per 100,000 hospital bed days (95% CI 15.0&#x02013;18.0). Fitting was conducted by allowing the model to run to endemic equilibrium, then running for a subsequent year of simulated incidence and fitting this to the average national incidence rates using a least squares algorithm. Results were then rescaled nationwide to account for the 136,508 hospital beds and 4122 adult critical care beds (most up-to-date ICU data were from 2021 and still included the transiently increased capacity in response to COVID-19 so the figure from end of 2019 was used) [<xref ref-type="bibr" rid="CR51">51</xref>]. Additional file 2 includes further details of equilibrial parametrisation as well as a global sensitivity analysis utilising Sobol&#x02019;s method [<xref ref-type="bibr" rid="CR52">52</xref>].</p></sec><sec id="Sec6"><title>Vaccination details and simulation</title><p id="Par30">PF-06425090 was designed to induce high levels of <italic>C. difficile</italic> toxin neutralising antibodies and has demonstrably reduced disease in preclinical assessments [<xref ref-type="bibr" rid="CR53">53</xref>]. In the CLOVER trial, the vaccine was administered in 3 doses at months 0, 1 and 6. In the simulation results, time point 0 corresponded with the third inoculation, hence with the first anticipated epidemiological impact following deployment of the completed dosage. Partial immunisations of those without completed dosage were omitted.</p><p id="Par31">In the trial, the two primary efficacy endpoints were first primary episode of CDI&#x02009;&#x02265;&#x02009;14 days following completion of the third dose and first primary episode of CDI&#x02009;&#x02265;&#x02009;14 days following completion of the second dose. While these primary endpoints were not met, the secondary endpoint of medically attended CDI (defined as participants with primary CDI episode that required CDI-related medical attention post-dose 3) yielded encouraging results (100% efficacy) albeit with low sample sizes (0 and 11 medically attended CDI among vaccinated and unvaccinated participants, respectively). In the model, &#x02018;diseased&#x02019; patients corresponded with patients who required medical attention for their CDI and an efficacy of only 90% was assumed. Sensitivity analyses were conducted whereby efficacy was assumed at 60% and 100% (see Additional files 3 and 4). It was additionally assumed that vaccination had no impact on colonisation risk&#x02014;only on the development of medically attended disease. In this way, their impact is on the parameter <italic>&#x003c3;</italic> (the rate of a colonised individual developing CDI per day). Thus, <italic>&#x003c3;</italic> is reduced by vaccination coverage (this is a proportion, VC) multiplied by vaccine efficacy (this is a proportion, VE): <italic>&#x003c3;</italic>&#x02009;&#x000d7;&#x02009;(1&#x02009;&#x02212;&#x02009;(VE&#x02009;&#x000d7;&#x02009;VC)).</p><p id="Par32">A previous phase 2, placebo-controlled, randomised, observer-blinded study was conducted between 2015 and 2017 using this vaccine [<xref ref-type="bibr" rid="CR54">54</xref>], and a recent extension study showed toxin A and B neutralising antibodies remained above pre-vaccination levels 48 months post vaccination schedule [<xref ref-type="bibr" rid="CR55">55</xref>]. Projected impacts explored two alternative scenarios: no waning within the modelled 10-year time horizon and sigmoidal waning that accommodated the initial lack of detectable waning but that resulted in halved efficacy after 6 years (~&#x02009;0% efficacy after 8 years). This latter scenario was achieved using a Weibull distribution with shape parameters of 10 and 2270 (days). Additional file 5 illustrates the dynamics of vaccination coverage according to both scenarios.</p><p id="Par33">Alternative scenarios of targeting different age groups were simulated using a no-vaccination scenario as the comparator. Initially, a 1-year time horizon was simulated to directly compare the impacts of targeting alternative age groups. Then, a more nuanced vaccination schedule was modelled for a 10-year time horizon in which those&#x02009;&#x0003e;&#x02009;74 years old were initially prioritised, then coverage was extended to those&#x02009;&#x0003e;&#x02009;64 year olds, ultimately switching to a top-up strategy for those newly turning 65 years old each year (see Fig. S2). Vaccine coverage was modelled to protect individuals in the community as well as hospital, meaning that, for example, 50% coverage of 65&#x02013;74 year olds equated to half of new admissions in this age category having received the vaccine. However, transmission within the community was not explicitly modelled due to the considerable uncertainty of this process (e.g. relative contribution of infected people versus contaminated foodstuffs [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. This means that any indirect benefits of vaccinations on reducing community-wide transmission is omitted, keeping the population-level impact of the intervention conservative.</p></sec><sec id="Sec7"><title>Economic analysis</title><p id="Par34">The consolidated Health Economic Evaluation Reporting Standards (CHEERS) were used for the analysis [<xref ref-type="bibr" rid="CR58">58</xref>]. The costs and benefits were analysed for introducing two vaccination schemes (i.e. with and without waning vaccine efficacy), compared to a do-nothing scenario, in England. Hospital costs and costs of years of life lost due to premature mortality averted per vaccine course were computed. Hospital costs comprised treatment drugs and bed-day ingredients. Following international clinical guidelines [<xref ref-type="bibr" rid="CR21">21</xref>], drugs were sourced from the National Institute for Health and Care Excellence &#x02018;NICE&#x02019; [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>]. Treatment costs were differentiated based on CDI recurrence and severity levels (low and high based on ICU admission). Vancomycin therapy, fidaxomicin- and bezlotoxumab-based treatments were incorporated [<xref ref-type="bibr" rid="CR21">21</xref>]. Hospital bed-day costs were extracted from the NHS reference cost for general wards [<xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>] and ICUs [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>] and were adjusted to patient&#x02019;s length of hospital stay. Costs due to premature mortality were estimated using the human capital approach by subtracting the standard life expectancy at the age of death, utilising UK National life tables for age-specific mortality rates [<xref ref-type="bibr" rid="CR67">67</xref>], minus individual&#x02019;s age at death and multiplied by country&#x02019;s gross domestic product (GDP) per capita. Costs were measured in 2023&#x000a3;. Quality-adjusted life years (QALYs) associated with each health state were also calculated. Crude future costs and benefits were estimated. Incremental QALYs gained and costs were computed for each vaccination strategy compared to the do-nothing scenario. Further details of the economic analysis including calculation details and parameters can be found in Additional file 6.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par35">Our model shows that vaccination targeting the older population enables substantial reductions in CDI cases, ICU admissions and deaths over a 1-year time horizon. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> illustrates the reduced returns in an alternative (unrealistic) scenario targeting the general population regardless of age (&#x02018;total population&#x02019;). The subpopulations over 64 and 74 years old respectively comprise 19% and 9% of England&#x02019;s total population. In general, targeting over 64 year olds achieved around four-fifths the impact of targeting the total population despite requiring one-fifth the vaccine doses, and targeting over 74 year olds achieved over half the impact despite requiring one-tenth the vaccine doses. The figure also highlights the indirect benefits of vaccines through transmission reduction. Conservatively, no impact of the vaccine was assumed on colonisation; these indirect impacts result from reduced diseased patients. When older subpopulations are targeted, indirect impacts increase with vaccine coverage. These indirect impacts can be considerable. For example, a strategy of vaccinating everyone over 64 years old reduced additional deaths by 147 (60%&#x02013;100% vaccine efficacy sensitivity analysis: 114&#x02013;155; see supplementary materials) through indirect impacts alone, compared to 772 (515&#x02013;858) through direct protection from CDI. This result does not hold for when the total population is targeted because at high coverage levels, the proportion of the population remaining unvaccinated (and able to enjoy indirect benefits) dwindles. In this scenario, maximum indirect benefits are achieved at middle coverage levels.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Simulated impacts of different vaccine coverage levels on annual <bold>A</bold> CDI cases, <bold>B</bold> ICU admissions and <bold>C</bold> deaths in England. Results are presented following 1-year simulations during which immunity was assumed not to wane. Colours correspond with different targeting strategies, including all age groups (&#x02018;total population&#x02019;, black), just those who were older than 64 years (dark grey) and just those who were older than 74 years old (light grey). The white spaces within the bars denote the additional outcomes (CDI cases, ICU admissions, deaths) averted among unvaccinated individuals, i.e. through indirect effects of the vaccine</p></caption><graphic xlink:href="12916_2025_4265_Fig2_HTML" id="MO2"/></fig></p><p id="Par36">A time horizon of 10 years was simulated for two vaccination scenarios whereby efficacy either did not wane or waned in a sigmoidal fashion. Under both scenarios, the same targeting strategy was simulated, prioritising older age groups because of the enhanced returns in health outcomes. Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows the projected epidemiological impact of vaccinating everyone over the age of 74 in year 0 (requiring 4.9 million vaccine courses, i.e. 4.9 million&#x02009;&#x000d7;&#x02009;3 doses per course&#x02009;=&#x02009;14.7 million doses), followed by 5 million courses in year 1 vaccinating those newly turning 75 and the remainder used for those aged 65&#x02013;74 years old, followed by 0.4 million courses each year from year 2 to top-up those newly turning 65 years old. The health economics corresponding with both vaccination scenarios are shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. In terms of hospital costs combined with years of life lost due to premature mortality costs, maximal gains are achieved by end of year 4 when &#x000a3;378 (&#x000a3;260-&#x000a3;416) is averted per vaccine course (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). This corresponded with 0.046 (0.035&#x02013;0.05) QALYs gained per course (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>The simulated impact on CDI prevalence per 100,000 population from a 10-year top-up vaccination strategy for <bold>A</bold> a vaccine that remains efficacious throughout and <bold>B</bold> a vaccine that wanes from the fourth year, following a Weibull distribution (see Methods). The darker lines represent simulations of the average CDI rates reported among hospitals in England, and the boundaries are from simulations of the 95% confidence intervals for reported CDI rates. &#x02018;Secondary CDI&#x02019; refers to primary recurrence whereas &#x02018;tertiary CDI&#x02019; refers to any subsequent recurrence</p></caption><graphic xlink:href="12916_2025_4265_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>The simulated impact on <bold>A</bold> costs averted and <bold>B</bold> QALYs gained, per vaccine course for both a no-wane (purple) and waning (orange) efficacy scenario over the 10-year vaccination horizon. Sensitivity analyses for vaccine efficacies of 60% and 100% are shown in the supplementary materials</p></caption><graphic xlink:href="12916_2025_4265_Fig4_HTML" id="MO4"/></fig></p><p id="Par37">Global sensitivity analysis of the model identified the parameters among <italic>C</italic>. <italic>difficile</italic>&#x02019;s life history to have greatest influence on the epidemiological outcomes of interest (see Additional file 2). The infection recovery rate (&#x02018;<italic>&#x003b5;</italic>&#x02019;) was most influential on ICU admissions and deaths, and the rate at which colonised individuals develop CDI (&#x02018;<italic>&#x003c3;</italic>&#x02019;) was most influential on medically attended cases.</p></sec><sec id="Sec9"><title>Discussion</title><p id="Par38">CDI is the leading cause of healthcare-associated infectious diarrhoea with increasing rates of community-associated disease, incurring enormous morbidity and mortality [<xref ref-type="bibr" rid="CR68">68</xref>], and resulting in considerable economic burden [<xref ref-type="bibr" rid="CR69">69</xref>]. Despite the urgent need of a safe, effective vaccine, development has been hampered by delays or withdrawals of late-stage vaccine candidates [<xref ref-type="bibr" rid="CR70">70</xref>]. The recent announcement by Pfizer detailing the effective reduction in medically attended CDI among recipients of its PF-06425090 vaccine [<xref ref-type="bibr" rid="CR71">71</xref>] is encouraging and this study sought to project the epidemiological and health-economic gains that might be anticipated as a result of deployment of a vaccine with a similar efficacy and safety profile.</p><p id="Par39">In line with previous studies, simulations suggested that considerable health returns can be expected from a safe, effective vaccine. For example, targeting only those over the age of 74 years old (i.e. 9% of England&#x02019;s population), with vaccine coverage of 100% and efficacy of 90%, can more than halve CDI cases and ICU admissions and reduce deaths by almost two-thirds for the entire population. Here, almost 10% of morbidity and 20% of mortality are averted through indirect effects. Toth et al. developed an agent-based simulation model of patients in a regional network of healthcare facilities to test the effects of a toxoid vaccine on <italic>C. difficile</italic> transmission and infection [<xref ref-type="bibr" rid="CR72">72</xref>]. Like the current study, they also showed noteworthy indirect benefits on the unvaccinated subpopulation whereby rates of protection were approximately 1/6 the protection afforded to those who were vaccinated [<xref ref-type="bibr" rid="CR72">72</xref>]. van Kleef et al. presented an individual-based transmission model of CDI in a high-risk hospital setting [<xref ref-type="bibr" rid="CR73">73</xref>]. They showed that vaccinating long-term care facility residents, elective surgery patients and patients with a history of ICU-onset CDI could reduce ward-onset CDI by 43%.</p><p id="Par40">Despite a relatively low, though sustained, prevalence of CDI in England&#x02019;s healthcare facilities (averaging&#x02009;~&#x02009;0.15%), the economic gains generated from simulated campaigns of vaccine rollout that prioritised older age groups were sizeable. Achieving effective coverage of all those over 64 years old can be expected to avert &#x000a3;378 annually in hospital costs combined with years of life lost due to premature mortality costs per vaccine course. This benefit is maintained for as long as the vaccine remains efficacious. This is an extremely encouraging result for the economic viability of a safe, efficacious <italic>C. difficile</italic> vaccine.</p><p id="Par41">Limitations of the study include limited knowledge of some epidemiological parameters, thus necessitating a global sensitivity analysis. Average infection recovery rate was determined to have the greatest influence on projections and reassuringly this is not a parameter with high levels of empirical uncertainty [<xref ref-type="bibr" rid="CR74">74</xref>]. An additional limitation is the assumption shared with previous models [<xref ref-type="bibr" rid="CR72">72</xref>] that the vaccine only reduced likelihood of disease development and that it had no impact on the susceptibility to acquisition of colonisation. Further, any indirect benefit of vaccinations on reducing community-based transmission was omitted due to the considerable uncertainty around primary sources of infection within the community. The effect of these assumptions would be to generate overly conservative estimates for both the epidemiological and economic impacts from the vaccine. A further, important limitation was that clinical endpoints beyond the timeframe over which the CLOVER trial extension ran are unknown and so to model the vaccine&#x02019;s impact over useful time horizons two contrived, alternative scenarios were assumed to cover both a pessimistic and optimistic projection. Should longer term data on efficacy waning become available, the model can easily be updated to incorporate this information. Finally, there is conflicting evidence regarding the relative levels of transmission within ICUs compared to general wards: for several pathogens, transmission would be expected to be greater in ICUs [<xref ref-type="bibr" rid="CR75">75</xref>], but, for <italic>C. difficile</italic>, increased patient movement and room changes associated with general wards may in fact lead to greater environmental contamination [<xref ref-type="bibr" rid="CR76">76</xref>]. However, the model is structured flexibly and can be parametrised to reflect emerging evidence in this area.</p><p id="Par42">It is also important to note that the current model assumes endemic stability of <italic>C. difficile</italic> transmission and does not explicitly account for potential variability arising from sporadic outbreaks or the emergence of hypervirulent strains, such as ribotype 027, which have been associated with increased severity and transmissibility [<xref ref-type="bibr" rid="CR77">77</xref>]. These epidemiological dynamics could influence the long-term effectiveness of vaccination strategies and should be considered when interpreting the current findings [<xref ref-type="bibr" rid="CR78">78</xref>]. Establishing the impacts of alternative vaccination strategies for scenarios of hypervirulent strain outbreaks comprises important future work. Future research should also delineate differences in case ascertainment and disease severity between community- and hospital-onset CDI. This would corroborate the assumption in the current analysis of equivalent severity between CLOVER&#x02019;s medically attended CDI (both community- and hospital-onset) and simulated hospital-onset CDI.</p></sec><sec id="Sec10"><title>Conclusions</title><p id="Par43">Currently, there is an unmet need to mitigate the enormous global burden posed by <italic>C. difficile</italic>. This analysis concludes that should a safe, highly efficacious <italic>C. difficile</italic> vaccine be licensed, it could be positioned very well for providing considerable economical health benefits to England&#x02019;s population. Future work should expand the current analysis to other countries.</p></sec><sec id="Sec11" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4265_MOESM1_ESM.docx"><caption><p>Additional file 1: Setting the epidemiological proportions of new hospital admissions. Fig. S1 Setting the epidemiological proportions of new hospital admissions. Describes the calibration process to set proportions of new hospital admissions with CDI and colonisation, and the approach for ensuring stable ICU populations</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4265_MOESM2_ESM.docx"><caption><p>Additional file 2: Global sensitivity analysis. Fig. S2 Global sensitivity analysis of endemically stable epidemiological outcomes. Presents the Sobol total effect index for sensitivity analyses on key model parameters across outcomes: CDI-associated deaths, medically attended CDI cases and ICU admissions</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12916_2025_4265_MOESM3_ESM.docx"><caption><p>Additional file 3: Vaccine efficacy sensitivity analysis. Fig. S3 Vaccine impacts for 60% efficacy. Fig. S4 Vaccine impacts for 100% efficacy. Simulated annual reductions in CDI cases, ICU admissions and deaths under varying coverage and age-targeting strategies</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12916_2025_4265_MOESM4_ESM.docx"><caption><p>Additional file 4: Vaccine efficacy sensitivity analysis. Fig. S5 Economic analysis for 60% vaccine efficacy. Fig. S6 Economic analysis for 100% vaccine efficacy. Simulated costs averted and QALYs gained per vaccine course under no-wane and waning scenarios over 10 years</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12916_2025_4265_MOESM5_ESM.docx"><caption><p>Additional file 5: Vaccination schedules under alternative waning scenarios. Fig. S7 Alternative scenarios for vaccine waning and age-based rollout strategies. Compares no waning versus Weibull-function waning, showing coverage dynamics and age-prioritisation strategies over time</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="12916_2025_4265_MOESM6_ESM.docx"><caption><p>Additional file 6: Economic analysis. Tables S1&#x02013;S7. S1: Total bed costs per patient per day. S2: Treatment costs by severity. S3: Utility scores for CDI by patient and recurrence status. S4&#x02013;S5: Derivation of hospitalisation and costs. S6: Summary of total hospital costs per day. S7: Costs associated with years of life lost due to premature mortality. Describes cost derivation methodology, utility sourcing life-expectancy assumptions for QALY calculations</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>C. difficile</term><def><p id="Par5">Clostridioides difficile</p></def></def-item><def-item><term>CDI</term><def><p id="Par6"><italic>Clostridioides</italic><italic> difficile</italic> Infection</p></def></def-item><def-item><term>QALYs</term><def><p id="Par7">Quality-adjusted life years</p></def></def-item><def-item><term>ICU</term><def><p id="Par8">Intensive care unit</p></def></def-item><def-item><term>OR</term><def><p id="Par9">Odds ratio</p></def></def-item><def-item><term>FMT</term><def><p id="Par10">Faecal microbiota transfer</p></def></def-item><def-item><term>GI</term><def><p id="Par11">Gastrointestinal</p></def></def-item><def-item><term>GDP</term><def><p id="Par12">Gross domestic product</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Laith Yakob and Kasim Allel contributed equally to this work.</p></fn><fn><p><bold>Change history</bold></p><p>7/31/2025</p><p>The original article has been updated to move a paragraph of text to improve readability.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Nadia Minarovic for her contribution to this analysis.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Conceptualisation and design (L.Y., T.P.); Analysis and interpretation of data (L.Y., K.A., A.E.); Drafting the first manuscript (L.Y., K.A.); Supervision (L.Y., T.M., J.C.M., H.Y.); Critical revision of the paper (all authors). All authors revised the manuscript before submission.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was sponsored by Pfizer. Funders had no direct role in the conduct of the study or the data collection, management or analysis. As co-authors, funder representatives were involved in the preparation, review and approval of the manuscript for submission.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par44">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par45">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par46">LY and AE received research funds from Pfizer Inc to support the research detailed in this paper. TM, JCM and HY are employees of Pfizer Inc and may hold stocks or stock options.&#x000a0;Funders had no direct role in the conduct of the study or the data collection, management, or analysis. As co-authors, funder representatives were involved in the preparation, review, and approval of the manuscript for submission</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Viprey</surname><given-names>VF</given-names></name><name><surname>Davis</surname><given-names>GL</given-names></name><name><surname>Benson</surname><given-names>AD</given-names></name><name><surname>Ewin</surname><given-names>D</given-names></name><name><surname>Spittal</surname><given-names>W</given-names></name><name><surname>Vernon</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018</article-title><source>Euro Surveill</source><year>2022</year><volume>27</volume><issue>26</issue><fpage>2100704</fpage><pub-id pub-id-type="pmid">35775426</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Viprey VF, Davis GL, Benson AD, Ewin D, Spittal W, Vernon JJ, et al. A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018. Euro Surveill. 2022;27(26):2100704.<pub-id pub-id-type="pmid">35775426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">European Centre for Disease Prevention and Control. Clostridium difficile infections &#x02013; facts and surveillance. ECDC; 2021.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Viprey</surname><given-names>VF</given-names></name><name><surname>Granata</surname><given-names>G</given-names></name><name><surname>Vendrik</surname><given-names>KEW</given-names></name><name><surname>Davis</surname><given-names>GL</given-names></name><name><surname>Petrosillo</surname><given-names>N</given-names></name><name><surname>Kuijper</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018&#x02013;2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)</article-title><source>J Hosp Infect</source><year>2023</year><volume>131</volume><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">36462673</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Viprey VF, Granata G, Vendrik KEW, Davis GL, Petrosillo N, Kuijper EJ, et al. European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018&#x02013;2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI). J Hosp Infect. 2023;131:213&#x02013;20.<pub-id pub-id-type="pmid">36462673</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Rupnik</surname><given-names>M</given-names></name><name><surname>Wilcox</surname><given-names>MH</given-names></name><name><surname>Gerding</surname><given-names>DN</given-names></name></person-group><article-title>Clostridium difficile infection: new developments in epidemiology and pathogenesis</article-title><source>Nat Rev Microbiol</source><year>2009</year><volume>7</volume><issue>7</issue><fpage>526</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">19528959</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7(7):526&#x02013;36.<pub-id pub-id-type="pmid">19528959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Kyne</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>CP</given-names></name></person-group><article-title>Recurrent Clostridium difficile diarrhoea</article-title><source>Gut</source><year>2001</year><volume>49</volume><issue>1</issue><fpage>152</fpage><pub-id pub-id-type="pmid">11413124</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut. 2001;49(1):152.<pub-id pub-id-type="pmid">11413124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>MH</given-names></name><name><surname>Ahir</surname><given-names>H</given-names></name><name><surname>Coia</surname><given-names>JE</given-names></name><name><surname>Dodgson</surname><given-names>A</given-names></name><name><surname>Hopkins</surname><given-names>S</given-names></name><name><surname>Llewelyn</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life</article-title><source>J Antimicrob Chemother</source><year>2017</year><volume>72</volume><issue>9</issue><fpage>2647</fpage><lpage>2656</lpage><pub-id pub-id-type="pmid">28633368</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Wilcox MH, Ahir H, Coia JE, Dodgson A, Hopkins S, Llewelyn MJ, et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. J Antimicrob Chemother. 2017;72(9):2647&#x02013;56.<pub-id pub-id-type="pmid">28633368</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. CDC; 2019.</mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Public Health England. Thirty-day all-cause mortality following MRSA, MSSA and Gram-negative bacteraemia and C. difficile infections. PHE; 2020.</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>K</given-names></name><name><surname>Lawrence</surname><given-names>J</given-names></name><name><surname>Berry</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><etal/></person-group><article-title>Risk factors for primary Clostridium difficile infection; results from the observational study of risk factors for Clostridium difficile infection in hospitalized patients with infective diarrhea (ORCHID)</article-title><source>Front Public Health</source><year>2020</year><volume>8</volume><fpage>293</fpage><pub-id pub-id-type="pmid">32766196</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Davies K, Lawrence J, Berry C, Davis G, Yu H, Cai B, et al. Risk factors for primary Clostridium difficile infection; results from the observational study of risk factors for Clostridium difficile infection in hospitalized patients with infective diarrhea (ORCHID). Front Public Health. 2020;8:293.<pub-id pub-id-type="pmid">32766196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Abou Chakra</surname><given-names>CN</given-names></name><name><surname>Pepin</surname><given-names>J</given-names></name><name><surname>Sirard</surname><given-names>S</given-names></name><name><surname>Valiquette</surname><given-names>L</given-names></name></person-group><article-title>Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>e98400</fpage><pub-id pub-id-type="pmid">24897375</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS ONE. 2014;9(6):e98400.<pub-id pub-id-type="pmid">24897375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Bishop</surname><given-names>EJ</given-names></name><name><surname>Tiruvoipati</surname><given-names>R</given-names></name></person-group><article-title>Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines</article-title><source>J Antimicrob Chemother</source><year>2022</year><volume>78</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">36441203</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Bishop EJ, Tiruvoipati R. Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. J Antimicrob Chemother. 2022;78(1):21&#x02013;30.<pub-id pub-id-type="pmid">36441203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Bishop</surname><given-names>EJ</given-names></name><name><surname>Tiruvoipati</surname><given-names>R</given-names></name></person-group><article-title>Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines</article-title><source>J Antimicrob Chemother</source><year>2022</year><volume>78</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">36441203</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bishop EJ, Tiruvoipati R. Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. J Antimicrob Chemother. 2022;78(1):21&#x02013;30.<pub-id pub-id-type="pmid">36441203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Leffler</surname><given-names>DA</given-names></name><name><surname>Lamont</surname><given-names>JT</given-names></name></person-group><article-title>Clostridium difficile infection</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>16</issue><fpage>1539</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">25875259</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539&#x02013;48.<pub-id pub-id-type="pmid">25875259</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Furuya-Kanamori L, SAR, Paterson DL, Helms SK, Yakob L, McKenzie SJ, et al. Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory Clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J Clin Gastroenterol. 2017;51(2):145&#x02013;53.</mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">US Food and Drug Administration. FDA approves first orally administered fecal microbiota product for the prevention of recurrence of Clostridioides difficile infection. FDA; 2023.</mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Yakob</surname><given-names>L</given-names></name><name><surname>Riley</surname><given-names>TV</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Marquess</surname><given-names>J</given-names></name><name><surname>Clements</surname><given-names>ACA</given-names></name></person-group><article-title>Assessing control bundles for Clostridium difficile: a review and mathematical model</article-title><source>Emerg Microbes Infect</source><year>2014</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Yakob L, Riley TV, Paterson DL, Marquess J, Clements ACA. Assessing control bundles for Clostridium difficile: a review and mathematical model. Emerg Microbes Infect. 2014;3(1):1&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Brain</surname><given-names>D</given-names></name><name><surname>Yakob</surname><given-names>L</given-names></name><name><surname>Barnett</surname><given-names>A</given-names></name><name><surname>Riley</surname><given-names>T</given-names></name><name><surname>Clements</surname><given-names>A</given-names></name><name><surname>Halton</surname><given-names>K</given-names></name><etal/></person-group><article-title>Economic evaluation of interventions designed to reduce Clostridium difficile infection</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><issue>1</issue><fpage>e0190093</fpage><pub-id pub-id-type="pmid">29298322</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Brain D, Yakob L, Barnett A, Riley T, Clements A, Halton K, et al. Economic evaluation of interventions designed to reduce Clostridium difficile infection. PLoS ONE. 2018;13(1):e0190093.<pub-id pub-id-type="pmid">29298322</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Donskey</surname><given-names>CJ</given-names></name><name><surname>Dubberke</surname><given-names>ER</given-names></name><name><surname>Klein</surname><given-names>NP</given-names></name><name><surname>Liles</surname><given-names>EG</given-names></name><name><surname>Szymkowiak</surname><given-names>K</given-names></name><name><surname>Wilcox</surname><given-names>MH</given-names></name><etal/></person-group><article-title>CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: a phase 3, randomized trial investigating the efficacy and safety of a detoxified toxin A/B vaccine in adults 50 years and older at increased risk of Clostridioides difficile infection</article-title><source>Clin Infect Dis</source><year>2024</year><volume>79</volume><issue>6</issue><fpage>1503</fpage><lpage>1511</lpage><pub-id pub-id-type="pmid">39180325</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Donskey CJ, Dubberke ER, Klein NP, Liles EG, Szymkowiak K, Wilcox MH, et al. CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: a phase 3, randomized trial investigating the efficacy and safety of a detoxified toxin A/B vaccine in adults 50 years and older at increased risk of Clostridioides difficile infection. Clin Infect Dis. 2024;79(6):1503&#x02013;11.<pub-id pub-id-type="pmid">39180325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Versporten</surname><given-names>A</given-names></name><name><surname>Zarb</surname><given-names>P</given-names></name><name><surname>Caniaux</surname><given-names>I</given-names></name><name><surname>Gros</surname><given-names>MF</given-names></name><name><surname>Drapier</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey</article-title><source>Lancet Glob Health</source><year>2018</year><volume>6</volume><issue>6</issue><fpage>e619</fpage><lpage>e629</lpage><pub-id pub-id-type="pmid">29681513</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6(6):e619&#x02013;29.<pub-id pub-id-type="pmid">29681513</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>LC</given-names></name><name><surname>Gerding</surname><given-names>DN</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Bakken</surname><given-names>JS</given-names></name><name><surname>Carroll</surname><given-names>KC</given-names></name><name><surname>Coffin</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)</article-title><source>Clin Infect Dis</source><year>2018</year><volume>66</volume><issue>7</issue><fpage>e1</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">29462280</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-48.<pub-id pub-id-type="pmid">29462280</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>van Prehn</surname><given-names>J</given-names></name><name><surname>Reigadas</surname><given-names>E</given-names></name><name><surname>Vogelzang</surname><given-names>EH</given-names></name><name><surname>Bouza</surname><given-names>E</given-names></name><name><surname>Hristea</surname><given-names>A</given-names></name><name><surname>Guery</surname><given-names>B</given-names></name><etal/></person-group><article-title>European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults</article-title><source>Clin Microbiol Infect</source><year>2021</year><volume>27</volume><fpage>S1</fpage><lpage>21</lpage></element-citation><mixed-citation id="mc-CR21" publication-type="journal">van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27:S1-21.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Eyre</surname><given-names>DW</given-names></name><name><surname>Cule</surname><given-names>ML</given-names></name><name><surname>Wilson</surname><given-names>DJ</given-names></name><name><surname>Griffiths</surname><given-names>D</given-names></name><name><surname>Vaughan</surname><given-names>A</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>L</given-names></name><etal/></person-group><article-title>Diverse sources of C. difficile infection identified on whole-genome sequencing</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>13</issue><fpage>1195</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">24066741</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O&#x02019;Connor L, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med. 2013;369(13):1195&#x02013;205.<pub-id pub-id-type="pmid">24066741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Jolivet</surname><given-names>S</given-names></name><name><surname>Couturier</surname><given-names>J</given-names></name><name><surname>Grohs</surname><given-names>P</given-names></name><name><surname>Vilfaillot</surname><given-names>A</given-names></name><name><surname>Zahar</surname><given-names>JR</given-names></name><name><surname>Frange</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prevalence and risk factors of toxigenic Clostridioides difficile asymptomatic carriage in 11 French hospitals</article-title><source>Front Med (Lausanne)</source><year>2023</year><volume>10</volume><fpage>1191119</fpage></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Jolivet S, Couturier J, Grohs P, Vilfaillot A, Zahar JR, Frange P, et al. Prevalence and risk factors of toxigenic Clostridioides difficile asymptomatic carriage in 11 French hospitals. Front Med (Lausanne). 2023;10:1191119.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Galdys</surname><given-names>AL</given-names></name><name><surname>Nelson</surname><given-names>JS</given-names></name><name><surname>Shutt</surname><given-names>KA</given-names></name><name><surname>Schlackman</surname><given-names>JL</given-names></name><name><surname>Pakstis</surname><given-names>DL</given-names></name><name><surname>Pasculle</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Prevalence and duration of asymptomatic Clostridium difficile carriage among healthy subjects in Pittsburgh</article-title><source>Pennsylvania J Clin Microbiol</source><year>2014</year><volume>52</volume><issue>7</issue><fpage>2406</fpage><lpage>2409</lpage><pub-id pub-id-type="pmid">24759727</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Galdys AL, Nelson JS, Shutt KA, Schlackman JL, Pakstis DL, Pasculle AW, et al. Prevalence and duration of asymptomatic Clostridium difficile carriage among healthy subjects in Pittsburgh. Pennsylvania J Clin Microbiol. 2014;52(7):2406&#x02013;9.<pub-id pub-id-type="pmid">24759727</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Organisation for Economic Co-operation and Development. Length of hospital stay. OECD; 2021.</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>LV</given-names></name></person-group><article-title>Update on the changing epidemiology of Clostridium difficile-associated disease</article-title><source>Nat Clin Pract Gastroenterol Hepatol</source><year>2008</year><volume>5</volume><issue>1</issue><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">18174906</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2008;5(1):40&#x02013;8.<pub-id pub-id-type="pmid">18174906</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>C</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Kavanagh</surname><given-names>K</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name><name><surname>McCowan</surname><given-names>C</given-names></name><name><surname>Bennie</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cost burden of Clostridioides difficile infection to the health service: a retrospective cohort study in Scotland</article-title><source>J Hosp Infect</source><year>2020</year><volume>106</volume><issue>3</issue><fpage>554</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">32717202</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Robertson C, Pan J, Kavanagh K, Ford I, McCowan C, Bennie M, et al. Cost burden of Clostridioides difficile infection to the health service: a retrospective cohort study in Scotland. J Hosp Infect. 2020;106(3):554&#x02013;61.<pub-id pub-id-type="pmid">32717202</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Vendrik</surname><given-names>KEW</given-names></name><name><surname>Baktash</surname><given-names>A</given-names></name><name><surname>Goeman</surname><given-names>JJ</given-names></name><name><surname>Harmanus</surname><given-names>C</given-names></name><name><surname>Notermans</surname><given-names>DW</given-names></name><name><surname>de Greeff</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Comparison of trends in Clostridioides difficile infections in hospitalised patients during the first and second waves of the COVID-19 pandemic: a retrospective sentinel surveillance study</article-title><source>Lancet Reg Health Eur</source><year>2022</year><volume>19</volume><fpage>100444</fpage><pub-id pub-id-type="pmid">35801186</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Vendrik KEW, Baktash A, Goeman JJ, Harmanus C, Notermans DW, de Greeff SC, et al. Comparison of trends in Clostridioides difficile infections in hospitalised patients during the first and second waves of the COVID-19 pandemic: a retrospective sentinel surveillance study. Lancet Reg Health Eur. 2022;19: 100444.<pub-id pub-id-type="pmid">35801186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">NHS Digital. Critical care &#x02013; average length of stay by discharge day, 2019&#x02013;20. NHS Digital; 2021.</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">UK Health Security Agency. Thirty-day all-cause mortality following MRSA, MSSA and Gram-negative bacteraemia and C. difficile infections, 2020 to 2021. UKHSA; 2021. <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1039272/hcai-all-cause-fatality-report-2021.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1039272/hcai-all-cause-fatality-report-2021.pdf</ext-link></mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Feuerstadt</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>WW</given-names></name><name><surname>Drozd</surname><given-names>EM</given-names></name><name><surname>Dreyfus</surname><given-names>J</given-names></name><name><surname>Dahdal</surname><given-names>DN</given-names></name><name><surname>Wong</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Mortality, health care use, and costs of Clostridioides difficile infections in older adults</article-title><source>J Am Med Dir Assoc</source><year>2022</year><volume>23</volume><issue>10</issue><fpage>1721</fpage><lpage>8.e19</lpage><pub-id pub-id-type="pmid">35288083</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Feuerstadt P, Nelson WW, Drozd EM, Dreyfus J, Dahdal DN, Wong AC, et al. Mortality, health care use, and costs of Clostridioides difficile infections in older adults. J Am Med Dir Assoc. 2022;23(10):1721-8.e19.<pub-id pub-id-type="pmid">35288083</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Capuzzo</surname><given-names>M</given-names></name><name><surname>Volta</surname><given-names>C</given-names></name><name><surname>Tassinati</surname><given-names>T</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Valentin</surname><given-names>A</given-names></name><name><surname>Guidet</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hospital mortality of adults admitted to intensive care units in hospitals with and without intermediate care units: a multicentre European cohort study</article-title><source>Crit Care</source><year>2014</year><volume>18</volume><issue>5</issue><fpage>551</fpage><pub-id pub-id-type="pmid">25664865</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Capuzzo M, Volta C, Tassinati T, Moreno R, Valentin A, Guidet B, et al. Hospital mortality of adults admitted to intensive care units in hospitals with and without intermediate care units: a multicentre European cohort study. Crit Care. 2014;18(5):551.<pub-id pub-id-type="pmid">25664865</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>AK</given-names></name><name><surname>Al-Nassir</surname><given-names>WN</given-names></name><name><surname>Nerandzic</surname><given-names>MM</given-names></name><name><surname>Bobulsky</surname><given-names>GS</given-names></name><name><surname>Donskey</surname><given-names>CJ</given-names></name></person-group><article-title>Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection</article-title><source>Infect Control Hosp Epidemiol.</source><year>2010</year><volume>31</volume><issue>1</issue><fpage>21</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19929371</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010;31(1):21&#x02013;7.<pub-id pub-id-type="pmid">19929371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">UK Government. C. difficile infection: monthly data by prior trust exposure. Gov.uk; 2022.</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Ruiz M, Bottle A, Aylin PP. The Global Comparators project: international comparison of 30-day in-hospital mortality by day of the week. BMJ Qual Saf. 2015;24(8):492.</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Beinortas</surname><given-names>T</given-names></name><name><surname>Burr</surname><given-names>NE</given-names></name><name><surname>Wilcox</surname><given-names>MH</given-names></name><name><surname>Subramanian</surname><given-names>V</given-names></name></person-group><article-title>Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis</article-title><source>Lancet Infect Dis</source><year>2018</year><volume>18</volume><issue>9</issue><fpage>1035</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">30025913</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Beinortas T, Burr NE, Wilcox MH, Subramanian V. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis. 2018;18(9):1035&#x02013;44.<pub-id pub-id-type="pmid">30025913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Bromilow</surname><given-names>T</given-names></name><name><surname>Holmes</surname><given-names>H</given-names></name><name><surname>Coote</surname><given-names>L</given-names></name><name><surname>Woods</surname><given-names>S</given-names></name><name><surname>Pink</surname><given-names>J</given-names></name></person-group><article-title>Cost-effectiveness analysis of antimicrobial prescribing in the treatment of Clostridioides difficile infection in England</article-title><source>Pharmacoecon Open</source><year>2023</year><volume>7</volume><issue>5</issue><fpage>739</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">37306930</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Bromilow T, Holmes H, Coote L, Woods S, Pink J. Cost-effectiveness analysis of antimicrobial prescribing in the treatment of Clostridioides difficile infection in England. Pharmacoecon Open. 2023;7(5):739&#x02013;50.<pub-id pub-id-type="pmid">37306930</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Budgell</surname><given-names>EP</given-names></name><name><surname>Davies</surname><given-names>TJ</given-names></name><name><surname>Donker</surname><given-names>T</given-names></name><name><surname>Hopkins</surname><given-names>S</given-names></name><name><surname>Wyllie</surname><given-names>DH</given-names></name><name><surname>Peto</surname><given-names>TEA</given-names></name><etal/></person-group><article-title>Impact of antibiotic use on patient-level risk of death in 36 million hospital admissions in England</article-title><source>J Infect</source><year>2022</year><volume>84</volume><issue>3</issue><fpage>311</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">34963640</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Budgell EP, Davies TJ, Donker T, Hopkins S, Wyllie DH, Peto TEA, et al. Impact of antibiotic use on patient-level risk of death in 36 million hospital admissions in England. J Infect. 2022;84(3):311&#x02013;20.<pub-id pub-id-type="pmid">34963640</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Eyre</surname><given-names>DW</given-names></name><name><surname>Walker</surname><given-names>AS</given-names></name><name><surname>Wyllie</surname><given-names>D</given-names></name><name><surname>Dingle</surname><given-names>KE</given-names></name><name><surname>Griffiths</surname><given-names>D</given-names></name><name><surname>Finney</surname><given-names>J</given-names></name><etal/></person-group><article-title>Predictors of first recurrence of Clostridium difficile infection: implications for initial management</article-title><source>Clin Infect Dis</source><year>2012</year><volume>55</volume><issue>Suppl 2</issue><fpage>S77</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">22752869</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012;55(Suppl 2):S77-87.<pub-id pub-id-type="pmid">22752869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>PR</given-names></name><name><surname>Vaizey</surname><given-names>C</given-names></name><name><surname>Black</surname><given-names>CM</given-names></name><name><surname>Nicholls</surname><given-names>R</given-names></name><name><surname>Weston</surname><given-names>AR</given-names></name><name><surname>Bampton</surname><given-names>P</given-names></name><etal/></person-group><article-title>Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study</article-title><source>J Crohns Colitis</source><year>2014</year><volume>8</volume><issue>7</issue><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">24345767</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Gibson PR, Vaizey C, Black CM, Nicholls R, Weston AR, Bampton P, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohns Colitis. 2014;8(7):598&#x02013;606.<pub-id pub-id-type="pmid">24345767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Hammeken</surname><given-names>LH</given-names></name><name><surname>Baunwall</surname><given-names>SMD</given-names></name><name><surname>Dahlerup</surname><given-names>JF</given-names></name><name><surname>Hvas</surname><given-names>CL</given-names></name><name><surname>Ehlers</surname><given-names>LH</given-names></name></person-group><article-title>Health-related quality of life in patients with recurrent Clostridioides difficile infections</article-title><source>Ther Adv Gastroenterol</source><year>2022</year><volume>15</volume><fpage>17562848221078441</fpage></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Hammeken LH, Baunwall SMD, Dahlerup JF, Hvas CL, Ehlers LH. Health-related quality of life in patients with recurrent Clostridioides difficile infections. Ther Adv Gastroenterol. 2022;15:17562848221078440.</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Flaxman</surname><given-names>AD</given-names></name><name><surname>Michaud</surname><given-names>C</given-names></name><etal/></person-group><article-title>Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990&#x02013;2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><issue>9859</issue><fpage>2197</fpage><lpage>2223</lpage><pub-id pub-id-type="pmid">23245608</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990&#x02013;2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197&#x02013;223.<pub-id pub-id-type="pmid">23245608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Saltelli</surname><given-names>A</given-names></name></person-group><article-title>Making best use of model evaluations to compute sensitivity indices</article-title><source>Comput Phys Commun</source><year>2002</year><volume>145</volume><fpage>280</fpage><lpage>297</lpage></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Saltelli A. Making best use of model evaluations to compute sensitivity indices. Comput Phys Commun. 2002;145:280&#x02013;97.</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Saltelli</surname><given-names>A</given-names></name><name><surname>Annoni</surname><given-names>P</given-names></name><name><surname>Azzini</surname><given-names>I</given-names></name><name><surname>Campolongo</surname><given-names>F</given-names></name><name><surname>Ratto</surname><given-names>M</given-names></name><name><surname>Tarantola</surname><given-names>S</given-names></name></person-group><article-title>Variance based sensitivity analysis of model output. Design and estimator for the total sensitivity index</article-title><source>Comput Phys Commun.</source><year>2010</year><volume>181</volume><fpage>259</fpage><lpage>70</lpage></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Saltelli A, Annoni P, Azzini I, Campolongo F, Ratto M, Tarantola S. Variance based sensitivity analysis of model output. Design and estimator for the total sensitivity index. Comput Phys Commun. 2010;181:259&#x02013;70.</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Recurrent Clostridium difficile infection: risk factors, treatment, and prevention</article-title><source>Gut Liver</source><year>2019</year><volume>13</volume><issue>1</issue><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">30400734</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Song JH, Kim YS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13(1):16&#x02013;24.<pub-id pub-id-type="pmid">30400734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Xuan</surname><given-names>S</given-names></name><name><surname>Zangwill</surname><given-names>KM</given-names></name><name><surname>Ni</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Hay</surname><given-names>JW</given-names></name></person-group><article-title>Cost-effectiveness analysis of four common diagnostic methods for Clostridioides difficile infection</article-title><source>J Gen Intern Med</source><year>2020</year><volume>35</volume><issue>4</issue><fpage>1102</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">32016703</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Xuan S, Zangwill KM, Ni W, Ma J, Hay JW. Cost-effectiveness analysis of four common diagnostic methods for Clostridioides difficile infection. J Gen Intern Med. 2020;35(4):1102&#x02013;10.<pub-id pub-id-type="pmid">32016703</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">NHS Digital. Hospital admissions hit record high as population ages. NHS Digital; 2016. <ext-link ext-link-type="uri" xlink:href="https://digital.nhs.uk/news/news-archive/2016-news-archive/hospital-admissions-hit-record-high-as-population-ages">https://digital.nhs.uk/news/news-archive/2016-news-archive/hospital-admissions-hit-record-high-as-population-ages</ext-link></mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname><given-names>VG</given-names></name><name><surname>Bourgault</surname><given-names>AM</given-names></name><name><surname>Poirier</surname><given-names>L</given-names></name><name><surname>Lamothe</surname><given-names>F</given-names></name><name><surname>Michaud</surname><given-names>S</given-names></name><name><surname>Turgeon</surname><given-names>N</given-names></name><etal/></person-group><article-title>Host and pathogen factors for Clostridium difficile infection and colonization</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>18</issue><fpage>1693</fpage><lpage>1703</lpage><pub-id pub-id-type="pmid">22047560</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693&#x02013;703.<pub-id pub-id-type="pmid">22047560</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">National Audit Office. Discharging older patients from hospital. National Audit Office; 2016. <ext-link ext-link-type="uri" xlink:href="https://www.nao.org.uk/wp-content/uploads/2015/12/Discharging-older-patients-from-hospital-Summary.pdf">https://www.nao.org.uk/wp-content/uploads/2015/12/Discharging-older-patients-from-hospital-Summary.pdf</ext-link></mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>KB</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>Golding</surname><given-names>GR</given-names></name><name><surname>Pelude</surname><given-names>L</given-names></name><name><surname>Hizon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Characterization of healthcare-associated and community-associated Clostridioides difficile infections among adults, Canada, 2015&#x02013;2019</article-title><source>Emerg Infect Dis</source><year>2022</year><volume>28</volume><issue>6</issue><fpage>1128</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">35470794</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Du T, Choi KB, Silva A, Golding GR, Pelude L, Hizon R, et al. Characterization of healthcare-associated and community-associated Clostridioides difficile infections among adults, Canada, 2015&#x02013;2019. Emerg Infect Dis. 2022;28(6):1128&#x02013;36.<pub-id pub-id-type="pmid">35470794</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">British Medical Association. NHS hospital beds data analysis. BMA; 2022.</mixed-citation></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Sobol</surname><given-names>IM</given-names></name></person-group><article-title>Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates</article-title><source>Math Comput Simul</source><year>2001</year><volume>55</volume><issue>1</issue><fpage>271</fpage><lpage>280</lpage></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Sobol IM. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates. Math Comput Simul. 2001;55(1):271&#x02013;80.</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Donald</surname><given-names>RGK</given-names></name><name><surname>Flint</surname><given-names>M</given-names></name><name><surname>Kalyan</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Witko</surname><given-names>SE</given-names></name><name><surname>Kotash</surname><given-names>C</given-names></name><etal/></person-group><article-title>A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile</article-title><source>Microbiology (Reading)</source><year>2013</year><volume>159</volume><issue>Pt 7</issue><fpage>1254</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">23629868</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Donald RGK, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology (Reading). 2013;159(Pt 7):1254&#x02013;66.<pub-id pub-id-type="pmid">23629868</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Remich</surname><given-names>SA</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Gruber</surname><given-names>WC</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><etal/></person-group><article-title>A phase 2 study evaluating the safety, tolerability, and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy US adults aged 65 to 85 years</article-title><source>Clin Infect Dis</source><year>2019</year><volume>70</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Kitchin N, Remich SA, Peterson J, Peng Y, Gruber WC, Jansen KU, et al. A phase 2 study evaluating the safety, tolerability, and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy US adults aged 65 to 85 years. Clin Infect Dis. 2019;70(1):1&#x02013;10.</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Remich</surname><given-names>S</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Pride</surname><given-names>MW</given-names></name><name><surname>Brock</surname><given-names>L</given-names></name><etal/></person-group><article-title>A phase 2 extension study evaluating the immunogenicity, safety, and tolerability of 3 or 4 doses of a Clostridioides difficile vaccine in healthy US adults aged 65 to 85 years</article-title><source>J Infect Dis</source><year>2024</year><volume>229</volume><issue>2</issue><fpage>367</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">37531657</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Remich S, Kitchin N, Peterson J, Li P, Pride MW, Brock L, et al. A phase 2 extension study evaluating the immunogenicity, safety, and tolerability of 3 or 4 doses of a Clostridioides difficile vaccine in healthy US adults aged 65 to 85 years. J Infect Dis. 2024;229(2):367&#x02013;75.<pub-id pub-id-type="pmid">37531657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name></person-group><article-title>Community-acquired Clostridium difficile infection: an increasing public health threat</article-title><source>Infect Drug Resist</source><year>2014</year><volume>7</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24669194</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63&#x02013;72.<pub-id pub-id-type="pmid">24669194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Warriner</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Habash</surname><given-names>M</given-names></name><name><surname>Sultan</surname><given-names>S</given-names></name><name><surname>Weese</surname><given-names>SJ</given-names></name></person-group><article-title>Dissemination of Clostridium difficile in food and the environment: significant sources of C. difficile community-acquired infection?</article-title><source>J Appl Microbiol.</source><year>2017</year><volume>122</volume><issue>3</issue><fpage>542</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">27813268</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Warriner K, Xu C, Habash M, Sultan S, Weese SJ. Dissemination of Clostridium difficile in food and the environment: significant sources of C. difficile community-acquired infection? J Appl Microbiol. 2017;122(3):542&#x02013;53.<pub-id pub-id-type="pmid">27813268</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Husereau</surname><given-names>D</given-names></name><name><surname>Drummond</surname><given-names>M</given-names></name><name><surname>Augustovski</surname><given-names>F</given-names></name><name><surname>de Bekker-Grob</surname><given-names>E</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Carswell</surname><given-names>C</given-names></name><etal/></person-group><article-title>Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations</article-title><source>BMJ</source><year>2022</year><volume>376</volume><fpage>e067975</fpage><pub-id pub-id-type="pmid">35017145</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975.<pub-id pub-id-type="pmid">35017145</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence. Vancomycin medicinal forms. NICE; 2023. <ext-link ext-link-type="uri" xlink:href="https://bnf.nice.org.uk/drugs/vancomycin/medicinal-forms/">https://bnf.nice.org.uk/drugs/vancomycin/medicinal-forms/</ext-link></mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence. Fidaxomicin medicinal forms. NICE; 2023. <ext-link ext-link-type="uri" xlink:href="https://bnf.nice.org.uk/drugs/fidaxomicin/medicinal-forms/">https://bnf.nice.org.uk/drugs/fidaxomicin/medicinal-forms/</ext-link></mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence. Tigecycline medicinal forms. NICE; 2023. <ext-link ext-link-type="uri" xlink:href="https://bnf.nice.org.uk/drugs/tigecycline/medicinal-forms/">https://bnf.nice.org.uk/drugs/tigecycline/medicinal-forms/</ext-link></mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">NHS Digital. Hospital admitted patient care activity 2020&#x02013;21. NHS Digital; 2021.</mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">NHS England. National schedule of NHS costs &#x02013; year 2020&#x02013;21 &#x02013; NHS trust and NHS foundation trusts. NHS England; 2022.</mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Sandmann</surname><given-names>FG</given-names></name><name><surname>Davies</surname><given-names>NG</given-names></name><name><surname>Vassall</surname><given-names>A</given-names></name><name><surname>Edmunds</surname><given-names>WJ</given-names></name><name><surname>Jit</surname><given-names>M</given-names></name></person-group><article-title>The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><issue>7</issue><fpage>962</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">33743846</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Sandmann FG, Davies NG, Vassall A, Edmunds WJ, Jit M. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis. 2021;21(7):962&#x02013;74.<pub-id pub-id-type="pmid">33743846</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Guest</surname><given-names>JF</given-names></name><name><surname>Keating</surname><given-names>T</given-names></name><name><surname>Gould</surname><given-names>D</given-names></name><name><surname>Wigglesworth</surname><given-names>N</given-names></name></person-group><article-title>Modelling the annual NHS costs and outcomes attributable to healthcare-associated infections in England</article-title><source>BMJ Open</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>e033367</fpage></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Guest JF, Keating T, Gould D, Wigglesworth N. Modelling the annual NHS costs and outcomes attributable to healthcare-associated infections in England. BMJ Open. 2020;10(1):e033367.</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">NHS Improvement. NHS digital national schedule of reference costs 2016&#x02013;17. NHS Improvement; 2017. <ext-link ext-link-type="uri" xlink:href="https://improvement.nhs.uk/resources/reference-costs/">https://improvement.nhs.uk/resources/reference-costs/</ext-link></mixed-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Office for National Statistics. National life tables: UK. ONS; 2023. <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables">https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables</ext-link></mixed-citation></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Balsells</surname><given-names>E</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Leese</surname><given-names>C</given-names></name><name><surname>Lyell</surname><given-names>I</given-names></name><name><surname>Burrows</surname><given-names>J</given-names></name><name><surname>Wiuff</surname><given-names>C</given-names></name><etal/></person-group><article-title>Global burden of Clostridium difficile infections: a systematic review and meta-analysis</article-title><source>J Glob Health</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>010407</fpage><pub-id pub-id-type="pmid">30603078</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407.<pub-id pub-id-type="pmid">30603078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Ananthakrishnan</surname><given-names>AN</given-names></name></person-group><article-title>Economic burden and cost-effectiveness of therapies for Clostridioides difficile infection: a narrative review</article-title><source>Ther Adv Gastroenterol</source><year>2021</year><volume>14</volume><fpage>17562848211018654</fpage></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridioides difficile infection: a narrative review. Ther Adv Gastroenterol. 2021;14:17562848211018654.</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="other">Sanofi. Sanofi ends development of Clostridium difficile vaccine. Sanofi; 2017.</mixed-citation></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">Pfizer. Phase 3 CLOVER trial for Pfizer&#x02019;s investigational Clostridioides difficile vaccine indicates strong potential effect in reducing duration and severity of disease based on secondary endpoints. Pfizer; 2022.</mixed-citation></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Toth</surname><given-names>DJA</given-names></name><name><surname>Keegan</surname><given-names>LT</given-names></name><name><surname>Samore</surname><given-names>MH</given-names></name><name><surname>Khader</surname><given-names>K</given-names></name><name><surname>O&#x02019;Hagan</surname><given-names>JJ</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Modeling the potential impact of administering vaccines against Clostridioides difficile infection to individuals in healthcare facilities</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><issue>37</issue><fpage>5927</fpage><lpage>5932</lpage><pub-id pub-id-type="pmid">32703744</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Toth DJA, Keegan LT, Samore MH, Khader K, O&#x02019;Hagan JJ, Yu H, et al. Modeling the potential impact of administering vaccines against Clostridioides difficile infection to individuals in healthcare facilities. Vaccine. 2020;38(37):5927&#x02013;32.<pub-id pub-id-type="pmid">32703744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>van Kleef</surname><given-names>E</given-names></name><name><surname>Deeny</surname><given-names>SR</given-names></name><name><surname>Jit</surname><given-names>M</given-names></name><name><surname>Cookson</surname><given-names>B</given-names></name><name><surname>Goldenberg</surname><given-names>SD</given-names></name><name><surname>Edmunds</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>46</issue><fpage>5562</fpage><lpage>5570</lpage><pub-id pub-id-type="pmid">27727031</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">van Kleef E, Deeny SR, Jit M, Cookson B, Goldenberg SD, Edmunds WJ, et al. The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy. Vaccine. 2016;34(46):5562&#x02013;70.<pub-id pub-id-type="pmid">27727031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>G</given-names></name><name><surname>Guertin</surname><given-names>MH</given-names></name><name><surname>Laprise</surname><given-names>JF</given-names></name><name><surname>Drolet</surname><given-names>M</given-names></name><name><surname>Brisson</surname><given-names>M</given-names></name></person-group><article-title>Mathematical modeling of the transmission dynamics of Clostridium difficile infection and colonization in healthcare settings: a systematic review</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><issue>9</issue><fpage>e0163880</fpage><pub-id pub-id-type="pmid">27690247</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Gingras G, Guertin MH, Laprise JF, Drolet M, Brisson M. Mathematical modeling of the transmission dynamics of Clostridium difficile infection and colonization in healthcare settings: a systematic review. PLoS ONE. 2016;11(9):e0163880.<pub-id pub-id-type="pmid">27690247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Trilla</surname><given-names>A</given-names></name></person-group><article-title>Epidemiology of nosocomial infections in adult intensive care units</article-title><source>Intensive Care Med</source><year>1994</year><volume>20</volume><issue>3</issue><fpage>S1</fpage><lpage>4</lpage></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Trilla A. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med. 1994;20(3):S1-4.</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Komori</surname><given-names>K</given-names></name><name><surname>Yoshizawa</surname><given-names>S</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A molecular epidemiological and transmission analysis of Clostridioides difficile using draft whole-genome sequencing in a single hospital</article-title><source>BMC Infect Dis</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>989</fpage><pub-id pub-id-type="pmid">39289598</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Miyazaki T, Aoki K, Maeda T, Komori K, Yoshizawa S, Ishii Y, et al. A molecular epidemiological and transmission analysis of Clostridioides difficile using draft whole-genome sequencing in a single hospital. BMC Infect Dis. 2024;24(1):989.<pub-id pub-id-type="pmid">39289598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><name><surname>Miyajima</surname><given-names>F</given-names></name><name><surname>Roberts</surname><given-names>P</given-names></name><name><surname>Ellison</surname><given-names>L</given-names></name><name><surname>Pickard</surname><given-names>DJ</given-names></name><name><surname>Martin</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Emergence and global spread of epidemic healthcare-associated Clostridium difficile</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><issue>1</issue><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">23222960</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45(1):109&#x02013;13.<pub-id pub-id-type="pmid">23222960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="other">Knight DR, Kullin B, Androga GO, Barbut F, Eckert C, Johnson S, et al. Evolutionary and genomic insights into Clostridioides difficile sequence type 11: a diverse zoonotic and antimicrobial-resistant lineage of global One Health importance. mBio. 2019;10(2):e00446&#x02013;19.</mixed-citation></ref></ref-list></back></article>